Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects

Completed · Phase 1 · Has a placebo group

Conditions studied: Heart Failure, Type II; Diabetes

In brief

The investigators propose a small pilot proof of concept study to not only prove the existence of, but also probe the mechanisms underlying cardio-renal effects of empagliflozin in patients with heart failure. The investigators propose a 50 patient randomized, double-blind, placebo-controlled crossover study with patients with stable HF, type II diabetes and an eGFR \>45ml/min/1.73 m2 who are chronically receiving loop diuretics.

Key facts

Study ID

NCT03027960

Run by

Yale University

People needed

21

Starts

2017-06-27

Expected to finish

2019-06-01

Last updated by the study team

2020-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stable HF as defined by:
• No hospitalization for >60 days
• Stable HF medications for >=2 weeks, and stable diuretics for 4 weeks
• Opinion of HF cardiologist that the patient is at their optimal volume status
• Chronic daily oral loop diuretic dose >=20mg furosemide equivalents
• Diagnosis of type II diabetes
• Patient monitors blood glucose regularly at home
• eGFR >=45 mL/min/1.73 m2
• >=18 years old

You may not qualify if…

• Active titration of chronic HF medications expected during the study period
• Use of a non-loop diuretic, aside from an aldosterone antagonist (<=25mg spironolactone or <=50mg eplerenone)
• Critical stenotic valvular disease, complex congenital heart disease, or prior heart transplant
• History of diabetic ketoacidosis, "brittle" diabetes, and/or frequent hypoglycemia or severe hypoglycemic episodes requiring emergent intervention (ER visit or EMS response, glucagon administration or forced oral carbs) in the last 6 months
• History of bladder dysfunction, incontinence, pyelonephritis, urosepsis, or frequent urinary tract infections
• Anemia (defined as hemoglobin <8g/dL)
• Pregnancy or breastfeeding
• History of serious hypersensitivity
• Participation in another trial with an investigational drug within the 30 days prior to informed consent
• Use of another SGLT-2 inhibitor
• Appears unlikely, or unable to participate in the required study procedures, as assessed by the study PI or research RN (ex: clinically-significant psychiatric, addictive, or neurological disease)
• Inability to give written informed consent or follow study protocol

Where it is running

• Yale New Haven Hospital — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.